Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Completed 3Unknown 1Recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 112Myeloid 94Sarcoma 18Gastrointestinal 18Lymphoid 16Tumor-Agnostic 8Dermatologic 5Gynecologic 2CNS 2Head & Neck 1Breast 1

Conditions

Melanoma 4Mucosal Lentiginous Melanoma 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 194aldesleukin 148Interleukin-2 110fludarabine phosphate 106trametinib 85Temozolomide 83Dacarbazine 81fludarabine 80dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Magnetic Resonance Spectroscopy 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Specimen Handling 47Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
nilotinib × Dermatologic × Clear all
NCT04903119 2026-02-13

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

University of Kentucky

Phase 1 Recruiting
30 enrolled
Dermatologic

Melanoma

NCT00788775 2018-11-15

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Dana-Farber Cancer Institute

Phase 2 Completed
20 enrolled 14 charts
Dermatologic

Melanoma

NCT01395121 2017-06-08

NICAM

Institute of Cancer Research, United Kingdom

Phase 2 Completed
29 enrolled
Dermatologic

Mucosal Lentiginous Melanoma

NCT01028222 2015-12-30

TEAM

Novartis

Phase 2 Completed
55 enrolled 13 charts
Dermatologic

Melanoma

NCT01168050 2011-02-08

NILOMEL

Assistance Publique - Hôpitaux de Paris

Phase 2 Unknown
25 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡